<DOC>
	<DOCNO>NCT03099161</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary efficacy preladenant alone combination pembrolizumab ( pembro ) participant advance solid tumor respond prior therapy . This study do 2 part . Part 1 identify confirm recommend Phase II dose ( RP2D ) preladenant give alone combination pembrolizumab . Part 2 study determine safety efficacy preladenant combination pembrolizumab RP2D participant select solid tumor .</brief_summary>
	<brief_title>Study Preladenant ( MK-3814 ) Alone With Pembrolizumab ( MK-3475 ) Participants With Advanced Solid Tumors ( MK-3814A-062 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologically cytologicallydocumented , locally advanced metastatic solid malignancy respond least one five prior line cancer treatment regimens Has provide tumor tissue sample ( archival newly obtain core excisional biopsy tumor lesion ) Has measurable disease per RECIST 1.1 Has Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Females must pregnant Female male participant reproductive potential must agree use adequate contraception start first dose study therapy , throughout study period , 120 day last dose study therapy Has disease suitable local treatment administer curative intent Has receive previous treatment immunomodulatory agent ( e.g , anti Programmed Cell Death Receptor 1/ Programmed Cell Death Receptor Ligand 1 anticytotoxic Tlymphocyteassociated antigen4 ) discontinue treatment due Grade 3 high immunerelated adverse event Has receive previous treatment A2a receptor antagonist Has chemotherapy , definitive radiation , biological cancer therapy within 4 week first dose study therapy , recover Common Toxicity Criteria Adverse Events ( CTCAE ) grade 1 good adverse event Is currently participate participate study investigational agent use investigational device within 28 day first dose study therapy Is currently take take drug interfere Cytochrome P450 ( CYP ) 3A4 CYP2C8 grapefruit star fruit diet within 14 day first dose study therapy Is currently take take proton pump inhibitor within 5 day first dose study therapy Has diagnosis immunodeficiency receive chronic systemic steroid therapy form immunosuppressive therapy within 7 day first dose study therapy Is expect require form systemic localize antineoplastic therapy study Has history second malignancy , unless potentially curative treatment complete , evidence malignancy 5 year Has clinically active central nervous system metastases and/or carcinomatous meningitis History severe hypersensitivity reaction treatment monoclonal antibody/components study drug Has active infection require therapy History interstitial lung disease History ( noninfectious ) pneumonitis require steroid current pneumonitis History active tuberculosis Has active autoimmune disease require systemic treatment past 2 year Has receive livevirus vaccine within 30 day first dose study therapy Has know Human Immunodeficiency Virus ( HIV ) ( HIV 1 2 antibody ) and/or know active acute Hepatitis B C infection Has know psychiatric substance abuse disorder would interfere ability cooperate requirement study Is pregnant breastfeeding , expect conceive father child within project duration study Has fully recover effect major surgery without significant detectable infection Has surgery require general anesthesia within 2 week first dose study therapy Has surgery require regional/epidural anesthesia within 72 hour first dose study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Programmed Cell Death Receptor 1 ( PD-1 )</keyword>
	<keyword>Programmed Cell Death Receptor Ligand 1 ( PD-L1 )</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>